Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Crump

Blood

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood|May 19, 2012
Hitting the target in MCLMichael Crump
Blood|January 26, 2011
How I treat relapsed and refractory Hodgkin lymphomaJohn Kuruvilla, Armand Keating, Michael Crump
Blood|October 22, 2008
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaSusan M O'Brien, David F Claxton, Michael Crump, et al.
Blood|July 3, 2010
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart diseaseSten Myrehaug, Melania Pintilie, Lingsong Yun, et al.
Blood|March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Blood|July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood|May 19, 2012
Hitting the target in MCLMichael Crump
Blood|January 26, 2011
How I treat relapsed and refractory Hodgkin lymphomaJohn Kuruvilla, Armand Keating, Michael Crump
Blood|October 22, 2008
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemiaSusan M O'Brien, David F Claxton, Michael Crump, et al.
Blood|July 3, 2010
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart diseaseSten Myrehaug, Melania Pintilie, Lingsong Yun, et al.
Blood|March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Blood|July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Blood|August 5, 2017
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyMichael Crump, Sattva S Neelapu, Umar Farooq, et al.
Blood|June 26, 2015
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12John Kuruvilla, David A MacDonald, C Tom Kouroukis, et al.
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
Pageof 1